BNP PARIBAS ARBITRAGE/CALL/MODERNA/150/0.1/20.09.24 | Market Closed - Euronext Paris 10:00:01 05/06/2024 pm IST | ||
| 1.975 EUR | +21.54% |
|
| Current month | +27.01% | ||
| 1 month | +128.32% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 05/24/05 | 1.975 | +21.54% |
| 04/24/04 | 1.625 | 0.00% |
| 03/24/03 | 1.625 | +4.50% |
| 31/24/31 | 1.555 | -15.26% |
| 30/24/30 | 1.835 | +6.38% |
Real-time Euronext Paris
Last update June 05, 2024 at 10:00 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
BNP Paribas
|
| AH3NB | |
| ISIN | NLBNPFR1ZH95 |
| Date issued | 13/03/2024 |
| Strike | 150 $ |
| Maturity | 20/09/2024 (107 Days) |
| Parity | 10 : 1 |
| Emission price | 0.65 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.185 € |
|---|---|
| Lowest since issue | 0.385 € |
| Spread | 0.01 € |
| Spread % | 0.51% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
154.8
USD
Average target price
142.8
USD
Spread / Average Target
-7.77%
- Stock Market
- Warrants
- AH3NB Warrant
